Elon Musk Seeks $134 Billion in Lawsuit Against OpenAI and Microsoft Over Alleged Wrongful Gains 
Rio Tinto and BHP Agree to Explore Major Iron Ore Collaboration in Pilbara 
Microsoft Strikes Landmark Soil Carbon Credit Deal With Indigo Carbon to Boost Carbon-Negative Goal 
One Percent Rule Checklist For Safer Forex Trading Risk 
Google Seeks Delay on Data-Sharing Order as It Appeals Landmark Antitrust Ruling 
China Halts Shipments of Nvidia H200 AI Chips, Forcing Suppliers to Pause Production 
Jamie Dimon Signals Possible Five More Years as JPMorgan CEO Amid Ongoing Succession Speculation 
U.S. Transportation Board Sends Union Pacific–Norfolk Southern Merger Back for Revision 
TSMC Set to Post Record Q4 Profit as AI Chip Demand Accelerates 
TikTok Expands AI Age-Detection Technology Across Europe Amid Rising Regulatory Pressure 
Zhipu AI Launches GLM-Image Model Trained on Huawei Chips, Boosting China’s AI Self-Reliance Drive 
U.S. Lawmakers Raise Alarm Over Trump Approval of Nvidia AI Chip Sales to China 
xAI Restricts Grok Image Editing After Sexualized AI Images Trigger Global Scrutiny 
Boeing Reaches Tentative Settlement With Canadian Victim’s Family in 737 MAX Crash Lawsuits 
Toyota Industries Buyout Faces Resistance as Elliott Rejects Higher Offer 
Taiwan Issues Arrest Warrant for OnePlus CEO Over Alleged Illegal Recruitment Activities 
 & Lead Plaintiff Deadline - April 14, 2017 - EconoTimes)
NEW YORK, April 13, 2017 -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Galena Biopharma, Inc. (“Galena” or the “Company”) (NASDAQ:GALE) and certain of its officers, and is on behalf of purchasers of Galena securities from August 11, 2014 through January 31, 2017, inclusive (the “Class Period”). Such investors are advised to join this case by visiting the firm’s site: http://www.bgandg.com/gale.
This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws under the Securities Exchange Act of 1934 (the “Exchange Act”).
The Complaint alleges that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that: (1) Galena’s sales of Abstral were based on unsustainable sales and marketing practices; (2) such sales and marketing practices could subject Galena to a criminal investigation; and (3) consequently, Galena’s statements about its business, operations, and prospects, were false and misleading and/or lacked a reasonable basis.
A class action lawsuit has already been filed. If you wish to review a copy of the Complaint you can visit the firm’s site: http://www.bgandg.com/gale or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss in Galena you have until April 14, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff.
Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients. In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm’s expertise includes general corporate and commercial litigation, as well as securities arbitration. Attorney advertising. Prior results do not guarantee similar outcomes.
Contact: Bronstein, Gewirtz & Grossman, LLC Peretz Bronstein or Yael Hurwitz 212-697-6484 | [email protected]
